Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 352 followers
Latest posts
Last updated 3 minutes ago
Reminder: Invitation to Roche’s Virtual Ophthalmology Investor Event
5 minutes ago
We are pleased to invite investors and analysts to participate in our...
Roche’s Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer’s-related amyloid pathology
about 19 hours ago
Rules out Alzheimer’s pathology in early stages to enhance diagnostic pathway efficiencyProvides...
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
1 day ago
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Invitation to Roche’s Virtual Ophthalmology Investor Event
11 days ago
We are pleased to invite investors and analysts to participate in our...
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
11 days ago
Combination reduced the risk of disease progression or death by 46% and...
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
12 days ago
Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks
14 days ago
Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy...
Invitation to Roche’s 3rd Quarter Sales 2025 Presentation
21 days ago
Roche will publish its Sales for the 3rd Quarter of 2025 prior...
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
22 days ago
evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in...
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
25 days ago
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients...
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
26 days ago
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe...
Reminder: Invitation to Roche’s Pharma Day 2025
28 days ago
The Roche Investor Relations team would like to invite you to the...